INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 213 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,228,000 | +148.7% | 50,260 | +33.2% | 1.44% | +124.5% |
| Q3 2019 | $2,504,000 | -17.3% | 37,734 | -0.9% | 0.64% | -10.9% |
| Q2 2019 | $3,029,000 | -28.7% | 38,073 | +0.3% | 0.72% | -32.6% |
| Q1 2019 | $4,247,000 | +110.5% | 37,970 | +89.6% | 1.06% | +74.9% |
| Q4 2018 | $2,018,000 | -47.5% | 20,025 | -34.1% | 0.61% | -33.2% |
| Q3 2018 | $3,841,000 | +1019.8% | 30,395 | +1281.6% | 0.91% | +785.4% |
| Q4 2014 | $343,000 | -34.2% | 2,200 | 0.0% | 0.10% | -35.6% |
| Q3 2014 | $521,000 | 0.0% | 2,200 | 0.0% | 0.16% | -2.4% |
| Q2 2014 | $521,000 | -28.2% | 2,200 | 0.0% | 0.16% | -32.0% |
| Q1 2014 | $726,000 | +165.9% | 2,200 | -45.0% | 0.24% | +159.1% |
| Q4 2013 | $273,000 | – | 4,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |